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ABSTRACT
Objective To compare the clinical effectiveness of larval
therapy with a standard debridement technique
(hydrogel) for sloughy or necrotic leg ulcers.
Design Pragmatic, three armed randomised controlled
trial.
Setting Community nurse led services, hospital wards,
andhospitaloutpatientlegulcerclinicsinurbanandrural
settings, United Kingdom.
Participants 267 patients with at least one venous or
mixed venous and arterial ulcer with at least 25%
coverage of slough or necrotic tissue, and an ankle
brachial pressure index of 0.6 or more.
Interventions Loose larvae, bagged larvae, and hydrogel.
MainoutcomemeasuresTheprimaryoutcomewastimeto
healing of the largest eligible ulcer. Secondary outcomes
were time to debridement, health related quality of life
(SF-12), bacterial load, presence of meticillin resistant
Staphylococcusaureus,adverseevents,andulcerrelated
pain (visual analogue scale, from 0 mm for no pain to
150 mm for worst pain imaginable).
Results Time to healing was not significantly different
between the loose or bagged larvae group and the
hydrogel group (hazard ratio for healing using larvae v
hydrogel 1.13, 95% confidence interval 0.76 to 1.68;
P=0.54). Larval therapy significantly reduced the time to
debridement (2.31, 1.65 to 3.2; P<0.001). Health related
quality of life and change in bacterial load over time were
not significantly different between the groups. 6.7% of
participants had MRSA at baseline. No difference was
found between larval therapy and hydrogel in their ability
to eradicate MRSA by the end of the debridement phase
(75% (9/12) v 50% (3/6); P=0.34), although this
comparison was underpowered. Mean ulcer related pain
scores were higher in either larvae group compared with
hydrogel (mean difference in pain score: loose larvae v
hydrogel46.74(95%confidenceinterval32.44to61.04),
P<0.001;baggedlarvaevhydrogel38.58(23.46to53.70),
P<0.001).
Conclusions Larval therapy did not improve the rate of
healingofsloughyornecroticlegulcersorreducebacterial
load compared with hydrogel but did significantly reduce
the time to debridement and increase ulcer pain.
Trial registration Current Controlled Trials
ISRCTN55114812 and National Research Register
N0484123692.
INTRODUCTION
Venous leg ulcers develop from underlying venous
disease and are one of the most common chronic
wound types.
1 High compression bandaging is effec-
tive but only about 50% of leg ulcers are healed within
16 weeks, leaving scope for further improvements.
2-4
An important aspect of wound management is
thought to be removal of devitalised tissue from the
surface of the ulcer; a process called debridement.
56It
has been suggested that larval therapy debrides
wounds more swiftly than standard treatments
78 as
well as stimulating healing,
9-12 reducing bacterial
load,
13-17 and eradicating meticillin resistant Staphylo-
coccus aureus.
18 Larvae used for medicinal purposes are
available in loose and bagged formulations. Although
larvaltherapyisincreasinglyusedithasbeenevaluated
in just one published randomised controlled trial,
whichincludedonly12 patientswithvenouslegulcers
and reported debridement rather than healing as the
surrogate outcome.
19 Evidence for any antimicrobial
activity with use of larvae comes mainly from
laboratory studies.
14-16
We undertook a randomised controlled trial to
evaluate the clinical and cost effectiveness of larval
therapy compared with a standard debridement
treatment (hydrogel) on time to complete healing of
leg ulcers, time to debridement, cost of treatments,
health related quality of life (including ulcer pain), and
microbiology. The economic evaluation is reported in
the accompanying paper.
20
METHODS
This was a pragmatic multicentre, randomised, open
trialwithequalrandomisation,carriedoutin22centres
in the United Kingdom from July 2004 to May 2007.
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community nurse caseloads, hospital wards, and
hospital outpatient departments (for example, derma-
tology or surgery). Participants gave written informed
consent. Eligible participants had venous or mixed
venous and arterial leg ulcers (assessed as an ankle
brachial pressure index ≥0.6) with at least 25% of the
wound covered by slough or necrotic tissue (larval
therapy would not normally be used on wounds with
less coverage). We considered ulcers with an area of 5
cm
2orlessaseligibleiftheywerenon-healing(defined
as no change in area over the preceding month). If a
patienthadmultipleulcerswechosethelargesteligible
ulcer as the reference lesion. Patients were excluded if
they were pregnant or lactating, were allergic to
hydrogel,had grossly oedematous legs, or were taking
anticoagulants (contraindicated with larval therapy).
After consenting to the trial, participants were
randomised to receive either loose larvae (Zoobiotic;
Bridgend, Wales), bagged larvae (Biomonde; Barsbüt-
tel, Germany), or hydrogel (Purilon; Coloplast, Den-
mark), with nurses using a remote, telephone
randomisation service provided by York Trials Unit
(allocationwasthereforefullyconcealed).Randomisa-
tionwasdoneusingpermutedblockswithstratification
by trial centre and ulcer area (≤5c m
2 or >5 cm
2). A
computer programmer, who was not involved in the
data analysis, created the randomisation program
using randomly permuted blocks with block sizes of
three and six.
Interventions
Nurseswereencouragedtoconsiderallparticipantsfor
compression and to use four layer bandaging
4 unless
contraindicated by ankle brachial pressure index or
patient tolerance.
WeusedsterileLuciliasericatalarvae.Thenumberof
larvae required for each application was determined
from manufacturers’ guides. Larvae were left on the
ulcerforthreeorfourdays,andnursescouldassessthe
participant during this period. Participants could not
receive compression bandaging while larvae were in
situ. If further larval therapy was required on removal
of the dressing, hydrogel and the participant’s usual
bandagewereappliedwhilemorelarvaewereordered.
Participants in the control group received hydrogel
covered with a knitted viscose dressing as well as
compressiondependingontheanklebrachialpressure
index and patient tolerance. Frequency of application
was decided by the treating nurse.
The randomised treatment was applied in the
debridement phase: this ended either when
Assessed for eligibility (n=1712)
Randomised (n=267)
Excluded (n=1445):
  Already been in larval trial (n=4)
  Pregnant or breast feeding or of childbearing age (n=13)
  In other leg ulcer trial (n=3)
  Allergy to hydrogel (n=6)
  Uncontrolled diabetes (n=32)
  Ankle brachial pressure index < 0.6 (n=129)
  Grossly oedematous legs (n=56)
  Ulcer < 5cm2 (n=205)
  Ulcer with < 25% slough (n=504)
  Will not consider larval therapy (n=85)
  Unwilling or unable to give informed consent (n=121)
  Aged less than 18 (n=2)
  Receiving an anticoagulant (n=30)
  Multiple reasons (n=255)
Allocated to hydrogel (n=87):
  Received allocated treatment (n=78)
Treatment not received (n=9):
  Never applied (n=2)
  Hospital admission (n=2)
  Trial withdrawal (n=1)
  Reason unknown (n=4)
Allocated to bagged larvae (n=86):
  Received allocated treatment (n=82)
Treatment not received (n=4): 
  Refused larvae (n=1)
  Hospital admission (n=1)
  Reason unknown (n=2)
Allocated to loose larvae (n=94):
  Received allocated treatment (n=88)
Treatment not received (n=6):
  Withdrew on day of randomisation (n=1)
  Ulcer improved (n=1)
  Patient died (n=1)
  Reason unknown (n=3)
Withdrew from treatment (n=34):
  Ulcer area increased (n=2)
  Slough increased (n=16)
  Patient request (n=5)
  Withdrawal from treatment and follow-up
    assessments (n=4)
  Adverse treatment reaction (n=7)
Withdrew from treatment (n=36):
  Ulcer area increased (n=1)
  Slough increased (n=19)
  Patient request (n=4)
  Withdrawal from treatment and follow-up
    assessments (n=3)
  Adverse treatment reaction (n=9)
Withdrew from treatment (n=39):
  Ulcer area increased (n=2)
  Slough increased (n=19)
  Patient request (n=6)
  Withdrawal from treatment and follow-up
    assessments (n=6)
  Adverse treatment reaction (n=5)
  Patient was dying (n=1)
Included in primary analysis (n=87) Included in primary analysis (n=86) Included in primary analysis (n=94)
Fig 1 | Flow of participants through trial
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beforedebridement(classifiedaswithdrawalfromtrial
treatment).Inthephaseafterdebridement,participants
received a standard knitted viscose dressing with or
without compression. The maximum length of follow-
up was 12 months, although some participants who
were randomised towards the end of recruitment had
follow-up of between six and 12 months. We stopped
collecting routine clinical data for participants whose
reference ulcer had healed but asked them to continue
completing questionnaires on quality of life and use of
resources.
Outcome measurements
The primary outcome was time to complete healing of
the reference ulcer. Ulcer healing was defined as
complete epithelial cover in the absence of a scab
(eschar), which was assessed by the nurse with
independent corroboration by another nurse one
week later. In the event of disagreement, treatment
continued until agreement was reached on healing
status. Nurses took digital photographs weekly for six
months and then monthly. These were assessed
centrallytoascertainhealingstatusbytwoindependent
assessors, masked to treatment group.
Secondary outcomes were time to debridement of
the ulcer, health related quality of life, microbiology
(bacterial load and MRSA), adverse events, and ulcer
related pain. Debridement was defined as a cosmeti-
cally clean wound. Nurses recorded the date a wound
haddebrided.Debridementstatuswasalsoassessedby
masked independent assessors using digital photo-
graphs. We used the SF-12, previously found to be
sensitive to changes in the healing status of venous
ulcers,
21tomeasureparticipants’perceptionsofhealth
related quality of life both at the baseline assessment
and at three, six, nine, and 12 months.
Microbiological swabs were taken at baseline, after
removalofeachtrialdebridementtreatmentduringthe
first month (if the ulcer debrided within one month
then weekly until one month), and then monthly until
healingorcompletionofthetrial.Laboratoryanalysis,
blind to treatment, measured total bacterial load (10
x
copies/ml) and the presence or absence of MRSA.
Weclassedadverseeventsasseriousornon-serious.
Some events were always classified as serious (death,
lifethreateningevent,admissionto hospital,persistent
or significant disability or incapacity); the seriousness
of other events (for example, infection and deteriora-
tion of the wound) was judged by the treating nurse.
Health professionals indicated whether or not they
believedtheeventwasrelatedtotrialtreatment.Onthe
basis of reports in the literature and our earlier trial
(VenUS I),
4 we established a list of possible treatment
related adverse events a priori (pressure damage,
maceration, excoriation and infection ulcer related
pain, ulcer deterioration).
Participantsrecordedulcerrelatedpainoverthepast
24 hours on a visual analogue scale at baseline and at
first removal of the debridement treatment. The scale
ranged from no pain (0 mm) to worst pain imaginable
(150 mm).
Statistical analysis
All analyses were done in SAS version 9.1, and
significance testing used a two sided 5% significance
level.
We determined that we required 370 participants to
detect a reduction in median healing time from 20 to
12.7weekswith90%powerwhileallowingfor15%loss
to follow up, or 270 participants to detect the same
difference with 80% power. The estimated 20 week
healing time for the control group and the difference
between groups was based on the results of VenUS I.
4
Weinitiallycomparedtimetodebridementandtime
to healing between the three treatment groups using a
logranktest.Thesetreatmenteffectswereexploredina
Table 1 |Baseline characteristics of patients with leg ulcer allocated to one of three treatments
for debridement: loose larvae, bagged larvae, or hydrogel. Values are numbers (percentages)
of participants unless stated otherwise
Characteristics
Loose larvae
(n=94)
Bagged larvae
(n=86)
Hydrogel
(n=87)
Overall
(n=267)
Men 36 (38.3) 29 (33.7) 44 (50.6) 109 (40.8)
Mean (SD) age (years) 74.1 (12.9) 73.5 (12.2) 74.3 (12.8) 74.0 (12.6)
Area of ulcer (cm
2):
≤5 23 (24.5) 20 (23.3) 22 (25.3) 65 (24.3)
>5 71 (75.5) 66 (76.7) 65 (74.7) 202 (75.7)
Median (range) area of ulcer
(cm
2)*
12.2 (0.6-174.9) 17.3 (1.8-197.9) 12.2 (1.0-116.8) 13.2 (0.6-197.9)
Duration of ulcer (months):
≤6 33 (35.1) 46 (53.5) 35 (40.2) 114 (42.7)
>6 61 (64.9) 40 (46.5) 52 (59.8) 153 (57.3)
Median (range) duration of
ulcer (months)*
9.0 (1.0-240.0) 6.0 (1.0-204.0) 8.0 (1.0-372.0) 7.0 (1.0-372.0)
ABPI, treatment:
≥0.8, high compression 50 (53.2) 46 (53.5) 61 (70.1) 157 (58.8)
≥0.8, lower or no
compression
31 (33.0) 30 (34.9) 17 (19.5) 78 (29.2)
0.6-0.8 13 (13.8) 10 (11.6) 9 (10.3) 32 (12.0)
ABPI=ankle brachial pressure index.
*Median presented as data were skewed.
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Fig 2 | Kaplan Meier plot of time to ulcer healing after larval
therapy (loose and bagged larvae arms combined) compared
with hydrogel
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sation stratification factors (centre, baseline ulcer area)
as well as prognostic variables (duration of ulcer and
ulcertype:anklebrachialpressureindex≥0.8andhigh
compression; ankle brachial pressure index ≥0.8 and
lower or no compression; ankle brachial pressure
index0.6to0.8).Aprioriwedecidedthatifwefoundno
evidence of a difference between loose and bagged
larvae groups then we would present the hazard ratios
and95%confidenceintervalsforlarvaltherapyoverall
(looseand baggedlarvaegroupscombined)compared
with hydrogel. The proportional hazards assumption
was checked.
We calculated the physical component summary
scoreandmentalcomponentsummaryscoreoftheSF-
12foreachparticipantanduseddescriptivestatisticsto
summarise these at each assessment. The standardised
areas under the curve (area under the curve
22 for each
participant adjusted for the duration of available data)
were reported for the larvae and hydrogel groups and
compared using a Wilcoxon rank sum test. Values
were compared with those of age specific norms,
available for the United States.
23
Data on bacterial load were log transformed. We
usedarepeatedmeasuresregressionmodeltocompare
changes in bacterial load over time between the larvae
and hydrogel groups. Time of the ulcer swab was a
continuous measure and we included a quadratic term
to test if the effects of time were non-linear. We
considered treatment (larvae or hydrogel), time, base-
lineulcerarea,ulcertype,anddurationofulcerasfixed
effects and participants as random effects. The inter-
action between treatment and time was also assessed.
Weanalysedbacterialloadtotheendofthetrialandto
the end of the debridement phase.
We used Fisher’s exact test to compare the propor-
tion of participants (positive for MRSA at baseline)
with MRSA eradicated by the end of the debridement
phase between larvae and hydrogel groups. This was
repeated for the proportion of participants who were
negative for MRSA at baseline but who tested positive
for MRSA at any follow-up assessment.
Using a negative binomial model and adjusting for
the same covariates as the primary analyses we
compared the numbers of adverse events in each
participant between treatment groups. We also com-
pared treatment groups for ulcer related pain during
the 24 hours before the first removal of the debride-
ment treatment (measured on a visual analogue scale),
using linear regression and adjusting for baseline pain
score, ulcer area, duration of ulcer, and ulcer type.
RESULTS
BetweenJuly2004andMay2007,1712peoplewithleg
ulcers were screened and 267 (15.6%) randomised
from18centres:94tolooselarvae,86tobaggedlarvae,
and87tohydrogel.Theremainingfourcentresdidnot
recruit participants. Figure 1 shows the flow of
participants through the trial and table 1 summarises
their baseline characteristics.
Time to ulcer healing did not differ between the
groups(logranktest1.00,df=2,P=0.62).Intheadjusted
analysis, healing rates did not differ between the loose
and the bagged larvae arms (χ
2 0.19, df=1, P=0.66).
Resultsarethereforepresentedforlarvaeoverall(loose
and bagged larvae arms combined) compared with
hydrogel. The median time to healing in the larvae
group was 236 days (95% confidence interval 147 to
292) and in the hydrogel group was 245 days (166 to
upper limit not estimable). Figure 2 shows the Kaplan
Meier survival curve for time to healing of ulcers in
both groups.
Thehazardratiofromtheadjustedanalysisforlarvae
compared with hydrogel was 1.13 (95% confidence
interval 0.76 to 1.68, P=0.54), indicating a slightly
increased likelihood of healing in the larvae group,
althoughthiswasnotstatisticallysignificant.Whenthe
analysis was repeated using the date of healing as
recorded by the nurses on the patient record forms the
conclusions remained the same.
Time to debridement differed significantly between
the three groups (25.38, df=2, log rank test P<0.001).
Themediantimetodebridementwithlooselarvaewas
shorter(14days,95%confidenceinterval10to17)than
with bagged larvae (28 days, 13 to 55) and with
hydrogel(72 days, 56 to 131). When loose and bagged
larvae were compared in the adjusted analysis, how-
ever, the difference in time to debridement was not
significant (χ
2 1.52, df=1, P=0.22). Figure 3 shows the
Kaplan Meier curve for time to debridement in both
groups.
The rate of debridement at any time in either larvae
groups wasabout twice that ofthe hydrogelgroup;the
hazard ratio for the combined larvae group compared
with hydrogel was 2.31 (95% confidence interval 1.65
to 3.24, P<0.001).
The mean baseline physical component summary
scoreforthecombinedlarvaegroupwas33.3(SD11.4)
and for the hydrogel group was 35.9 (SD 11.5). These
valueswerelowcomparedwiththe37.9(SD11.16)for
norm based scores of people aged 75 and over in the
US. The mean baseline mental component summary
scoreforthecombinedlarvaegroupwas46.9(SD12.3)
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Fig 3 | Kaplan Meier plot of time to debridement of ulcer using
larvae (loose and bagged combined) compared with hydrogel
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compared with 50.4 (11.66) for the general US
population. The physical component summary scores
did not differ between the groups (median area under
the curve 0.4. for the combined larvae group, −0.5 for
thehydrogelgroup,P=0.25),indicatingnoevidenceof
a difference between the two groups (fig 4). The result
for the mental component summary was: median area
under the curve −0.8 for the combined larvae group
and −0.7 for the hydrogel group (P=0.95, fig 4).
The average log bacterial count at baseline was 6.5
(about 3.1×10
6 copies/ml) and was similar across the
groups. The analysis of data collected from swabs
during the trial showed no evidence of a difference in
bacterial load over time between the combined larvae
group and the hydrogel group (difference in means
(larvae minus hydrogel) −0.06, 95% confidence inter-
val −0.24 to 0.12, P=0.75). There was evidence that
overallulcerbacterialloaddecreasedovertimeinboth
groups (P=0.01) but no evidence that reductions over
time were different between the groups (P=0.63).
Similar results were seen in the analysis of bacterial
load only up to the point of debridement.
The prevalence of MRSA at baseline was low, with
only 6.7% of participants (18/267) having a positive
swab at baseline: seven participants allocated to loose
larvae,fiveallocatedtobaggedlarvae,andsixallocated
tohydrogel.Ofthese,MRSAwaseradicatedduringthe
debridement phase in 57.1% (4/7) of participants
allocated to loose larvae, 100% (5/5) allocated to
bagged larvae, and 50% (3/6) allocated to hydrogel.
There was no evidence of a difference between the
combined larvae and the hydrogel groups (75% (9/12)
v 50% (3/6); P=0.34). Also, the number of participants
whowerenegativeforMRSAatbaselinebutpositiveat
one or more follow-up assessments did not differ
betweenthecombinedlarvaeandthehydrogelgroups
(7.1% (12/168) v 2.5% (2/81); Fisher’s exact test
P=0.16).
In total, 131 participants had 340 adverse events.Of
these, 13.8% were classed as serious, corresponding to
14.6% events with loose larvae, 13.5% with bagged
larvae, and 13.5% with hydrogel. More participants in
the combined larvae group experienced one or more
adverseeventsthan participantsin the hydrogelgroup
(51.7% v 43.7%) but this difference was not significant
(χ
2 2.65, df=1, P=0.10).
The mean ulcer related pain scores (for the 24 hours
before removal of first debridement treatment) for the
larvaegroupswereaboutdoublethoseofthehydrogel
group (table 2). After adjustment, significantly more
pain was experienced by participants in both larvae
groups (P<0.001) than in the hydrogel group.
DISCUSSION
We found no evidence that a phase of treatment with
looseorbaggedlarvaereducesthetimetohealingofleg
ulcers compared with hydrogel. The median healing
times (236 days for the larvae groups and 245 days for
the hydrogel group) were longer than in our previous
trial, where the median time to healing with four layer
bandaging was 92 days and with short stretch banda-
ging was 126 days. The most likely explanation for the
increasedhealingtimeinthecurrenttrial(VenUSII)is
that we restricted eligibility to the trial to patients with
sloughy and necrotic leg ulcers and ulcers associated
with more arterial disease than in the previous study.
We also found no evidence of a difference in health
related quality of life or bacterial load.
Our findings do, however, indicate that larvae are a
more effective debriding agent than hydrogel. This is
the firstreportof painassociatedwith larvaltherapyin
alargenumberofpatientswithlegulcers,withacontrol
group for comparison. Pain reported in the 24 hours
before removal of the first larvae treatment was
considered related to the procedure and was probably
transient and did not seem to impact on the health
related quality of life measurements made at three
monthly intervals.
The low rate of MRSA identified in these mainly
community dwelling patients with leg ulcers is
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Table 2 |Difference in ulcer related pain score at first removal of treatment (larvae minus
hydrogel)
Variables Estimate (SE) P value 95% CI
Treatment group:
Loose larvae (n=82): hydrogel (n=71) 46.74 (7.25) <0.001 32.44. to 61.04
Bagged larvae (n=70): hydrogel (n=71) 38.58 (7.67) <0.001 23.46 to 53.70
Baseline pain score 0.41 (0.07) <0.001 0.26 to 0.55
Area (log) 1.34 (2.94) 0.65 −4.41 to 7.10
Duration of ulcer (log) −4.23 (2.36) 0.07 −8.86 to 0.40
Bracketed values in first column are numbers of participants.
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2425 We
also showed that MRSA can be eradicated from leg
ulcers irrespective of whether larval therapy is used.
Strengths and limitations of study
We believe that this is the first randomised controlled
trialtoinvestigatetheeffectoflarvaltherapyonwound
healing and we used blinded outcome assessment to
protectagainstobserverbias.Althoughtrialevidenceis
limited, there are several non-randomised controlled
trials that led to the promotion of larval therapy as a
clinicallyeffectivetreatment
726-29;“effective”variously
definedasthepromotionofhealing,
10-123031promotion
of debridement,
8 reduction in number of micro-
organisms in the wound,
14-16 and reduction of MRSA
specifically.
16 The present trial provides a more robust
evidence base to explore these issues.
As we did not investigate debridement as a longer
term outcome we were unaware of how many ulcers
that did debride remained debrided. Furthermore,
although the current study is the first randomised
controlled trial we have identified to investigate and
publish data on the antimicrobial action of larval
therapy, we also recognise the limitations of the
methods used. We only investigated an association
betweenlarvaltherapyandtotalbacterialload.Beyond
identification of MRSA we did not have the resources
to carry out qualitative investigation of bacterial flora
so can not draw any conclusions about the impact of
larval therapy on other species.
Finally, as with many randomised controlled trials,
recruitment of sufficient numbers of eligible patients
wasachallengeandwedidnotreachourinitialsample
size despite an extension in time and funding. The
reasons for this are probably complex. Anecdotally,
nursesthoughttherewerefewerpatientswithlegulcers
than previously, attributing this to an increased use of
compression bandaging. Secondly, fewer ulcers than
we originally anticipated were sloughy. Indeed the
main single reason for exclusion of patients from the
trial was ulcers not containing sufficient slough. Since
this is a prerequisite for using larval therapy, our
experience suggests that doing a larger trial in the
United Kingdom would be challenging.
Possible explanations and implications for clinicians and
policymakers
We found no evidence to recommend the routine use
of larval therapy on sloughy leg ulcers to speed up
healingorreducebacterialload.Ifdebridementinitself
is a goal of treatment, such as before skin grafting or
other surgery, then larval therapy should be consid-
ered; however, it is associated with significantly more
pain than hydrogel. Future treatment decisions should
be fully informed by the finding that there is no
evidence of an impact on healing time.
Unanswered questions and future research
Thepresentstudysupportstheviewthatlarvaltherapy
is an effective debriding agent. However, the study
raises uncertainty about the role of debridement in the
care of leg ulcers. Although debridement is viewed as
animportantpartofpreparationofthewoundbed,data
describing the relation between debridement and
healing are sparse. Research is required to explore
the relation between debridement, healing, and
microbiology as well to better understand the value
of debridement as an outcome from the patient’s
perspective.
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